Bookbuilding IPO | ₹12 Cr | Listed at BSE SME | Tue, May 12, 2026 - Thu, May 14, 2026
Goldline Pharmaceutical IPO is a book build issue of ₹11.61 crores. The issue is entirely a fresh issue of 0.27 crore shares of ₹11.61 crore.
Goldline Pharmaceutical IPO bidding started from May 12, 2026 and ended on May 14, 2026. The allotment for Goldline Pharmaceutical IPO was finalized on May 15, 2026. The shares got listed on the BSE SME on May 19, 2026.
Goldline Pharmaceutical IPO is set final issue price at ₹43 per share. The lot size for an application is 3,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (6,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (9,000 shares), amounting to ₹3,87,000.
Cumulative Capital Pvt.Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Nirman Share Brokers Pvt.Ltd.
Refer to Goldline Pharmaceutical IPO RHP for detailed Information.
IPO Open
Tue, May 12, 2026
IPO Close
Thu, May 14, 2026
Issue Price
₹43 per share
Market Cap (Pre-IPO)
₹41.28 Cr
| IPO Date | 12 to 14 May, 2026 |
| Listed on | Tue, May 19, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹41 to ₹43 |
| Issue Price | ₹43 per share |
| Lot Size | 3,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 27,00,000 shares (agg. up to ₹12 Cr) |
| Reserved for Market Maker | 1,38,000 shares Nirman Share Brokers Pvt.Ltd. (agg. up to ₹0.5934 Cr) |
| Fresh Issue (Ex Market Maker) | 25,62,000 shares (agg. up to ₹11 Cr) |
| Net Offered to Public | 25,62,000 shares (agg. up to ₹11 Cr) |
| Share Holding Pre Issue | 69,00,000 shares |
| Share Holding Post Issue | 96,00,000 shares |
| BSE Script Code | 544759 |
| ISIN | INE1CLW01015 |
Goldline Pharmaceutical IPO comprises a total issue size of 27,00,000 shares. The net offer to the public is 25,62,000 shares, after excluding 1,38,000 shares allotted on a firm basis. Of the Net offer 12,72,000 (49.65%) are allocated to QIB, 3,90,000 (15.22%) allocated to NII 9,00,000 (35.13%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 12,72,000 | 49.65% | 47.11% |
| − Anchor Investor Shares Offered | 7,32,000 | 27.11% | |
| − QIB (Ex. Anchor) Shares Offered | 5,40,000 | 20.00% | |
| NII (HNI) Shares Offered | 3,90,000 | 15.22% | 14.44% |
| − bNII > ₹10L | 2,58,000 | 9.56% | |
| − sNII < ₹10L | 1,32,000 | 4.89% | |
| Retail Shares Offered | 9,00,000 | 35.13% | 33.33% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,38,000 | 5.11% | |
| Total Shares Offered | 27,00,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 6,000 shares and in multiples of 3,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 6,000 | ₹2,58,000 |
| Individual investors (IND) (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
Goldline Pharmaceutical IPO raises ₹3.15 crore from anchor investors. Goldline Pharmaceutical IPO Anchor bid date is May 11, 2026.
| Bid Date | Mon, May 11, 2026 |
| Shares Offered | 7,32,000 |
| Anchor Portion (₹ Cr.) | 3.15 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sun, Jun 14, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Thu, Aug 13, 2026 |
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Competitive Strengths:
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
| Amount in ₹ Crore | ||||
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹184.05 (-2.10%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹260.00 (+2.36%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹250.00 (-1.05%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹100.70 (+0.90%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹229.25 (-1.99%) |
| Asston Pharmaceuticals Ltd. | SME | ₹27.56 Cr | ₹123 | 17.83 | ₹124.95 | +1.59% | ₹73.97 (+0.00%) |
| Influx Healthtech Ltd. | SME | ₹58.57 Cr | ₹96 | 13.04 | ₹126.20 | +31.46% | ₹312.35 (+3.74%) |
| Astonea Labs Ltd. | SME | ₹37.67 Cr | ₹135 | 27.36 | ₹135.65 | +0.48% | ₹261.20 (+1.99%) |
| Accretion Pharmaceuticals Ltd. | SME | ₹29.75 Cr | ₹101 | 21.29 | ₹82.95 | -17.87% | ₹159.00 (+2.15%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹610.25 (-1.52%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,004.10 (-1.62%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.68 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,362.20 (+4.61%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹171.24 (+5.00%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.32 (-3.22%) |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company | 8.35 |
| 2 | General Corporate Purposes | 1.71 |
| 3 | Issue Expense | 1.55 |
| Total | 11.61 |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 21.02% | 35.83% |
| ROCE | 24.22% | 38.45% |
| Debt/Equity | 1.07 | 1.50 |
| RoNW | 17.99% | 27.37% |
| PAT Margin | 10.38% | 10.09% |
| EBITDA Margin | 19.41% | 20.78% |
| Price to Book Value | 3.47 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 4.11 | 3.09 |
| P/E (x) | 10.47 | 13.93 |
| Promoter Holding | 79.70% | 57.29% |
| Market Cap | ₹41.28 Cr. |
The Goldline Pharmaceutical IPO IPO subscription status. Full data available on IPOMatrix.com.
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| Total | 598.69 | 25,62,000 | 1,53,38,43,000 | 1,65,088 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager Fees | 0.30 |
| 2 | Underwriting Fees | 0.55 |
| 3 | Market Maker Fees | 0.03 |
| 4 | Brokerage, selling commission and upload Fees | 0.07 |
| 5 | Sponsor Bank Fees | 0.01 |
| 6 | Fees payable to Registrar to Offer | 0.02 |
| 7 | Fees payable to Legal Advisor | 0.05 |
| 8 | Statutory Advertisement Expenses | 0.06 |
| 9 | Fees payable for Marketing & distribution expenses | 0.32 |
| 10 | Statutory Printing Expenses | 0.01 |
| 11 | Regulators including stock exchanges Fees | 0.07 |
| 12 | Fees for Depositories | 0.04 |
| 13 | Peer Review Auditor Fees | 0.03 |
| Total | 1.55 |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹43.00 |
| Open | ₹59.75 |
| Low | ₹56.77 |
| High | ₹60.00 |
| Last Trade | ₹56.77 |
Lead Manager Reports
Goldline Pharmaceutical IPO is a SME IPO of 27,00,000 equity shares of the face value of ₹10 aggregating up to ₹12 Crores. The issue is priced at ₹43 per share. The minimum order quantity is 3000.
The IPO opens on Tue, May 12, 2026, and closes on Thu, May 14, 2026.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Goldline Pharmaceutical IPO using UPI as a payment gateway. Zerodha customers can apply in Goldline Pharmaceutical IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Goldline Pharmaceutical IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Goldline Pharmaceutical IPO opens on Tue, May 12, 2026 and closes on Thu, May 14, 2026.
Goldline Pharmaceutical IPO lot size is 3000, and the minimum amount required for application is ₹2,58,000, with 2 lots being the minimum application size.
You can apply in Goldline Pharmaceutical IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Goldline Pharmaceutical IPO will be done on Friday, May 15, 2026, and the allotted shares will be credited to your demat account by Mon, May 18, 2026. Check the Goldline Pharmaceutical IPO allotment status.
The Goldline Pharmaceutical IPO listing date is on Tue, May 19, 2026.
